NASDAQ: ALZN
Linkedin Facebook-f Twitter Instagram
Alzamend
  • About us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Scientific Advisory Board
  • Science
    • Product Pipeline
    • Publications
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
    • Contact Us
    • Careers
Menu
  • About us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Scientific Advisory Board
  • Science
    • Product Pipeline
    • Publications
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
    • Contact Us
    • Careers

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Presentations
  • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts
Oct 29, 2018 9:00am EDT

Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease

Oct 24, 2017 10:35pm EDT

Alzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage Clinicals

Jan 30, 2017 6:00am EST

USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders

Jan 09, 2017 6:00am EST

Alzamend Neuro™ Announces TV Icon Willie Aames as International Spokesperson

Jan 03, 2017 2:05pm EST

Alzamend Neuro Launches Regulation A+ Tier II SEC Qualified Offering

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Alzamend

Making Alzheimer’s
Just a Memory™

About

  • Overview
  • Management
  • Board of Directors

Investor Relations

  • Overview
  • News & Events
  • Company Info
  • Presentations
  • Financial Results
  • Stock Data
  • SEC Filings
  • Governance

Other

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Safe Harbor

© 2016-23 Alzamend Neuro, Inc. All rights reserved.

Twitter Facebook-f Instagram Linkedin